MPI-1121

N/A

Report date: 2022/05/10 11:43:44
NME

Base Information

Drug NameMPI-1121
Drug Alias NameMPI1121
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCathepsin L inhibitorsSARS-CoV-2-3C-like-proteinase inhibitors
TargetsCathepsin LSARS-CoV-2-3C-like-proteinase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTexas A&M University
China Registration ClassN/A

Develop Information

Active CompaniesSorrento Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A